Takeda Integrates Procurement and Enhances Drug Production with AI
Takeda Pharmaceuticals, a 240-year-old pharmaceutical firm based in Tokyo, Japan, has implemented AI in key areas of its operations to drive efficiency and innovation. Post its merger with Shire, Takeda optimized its procurement process using Bizagi's Intelligent Process Automation (IPA), integrating supplier data while leveraging AI-driven technologies like predictive analytics and Robotic Process Automation (RPA). Additionally, in its Switzerland branch, Takeda used AI-powered statistical tools—Partial Least Squares (PLS) regression and Classification and Regression Trees (CART) decision trees—to enhance blood clot drug production by improving cell culture yields. These developments indicate Takeda's strategic embrace of advanced AI solutions to streamline operations and optimize pharmaceutical processes.
- Organization
- Takeda Pharmaceuticals
- Industry
- Pharma
- Location
- Japan
- Published
- May 2025
Why do we believe this deployment?Customer identity, provider attribution, maturity, and source checks
- Customer
- Takeda Pharmaceuticals
- Provider
- Microsoft
- Maturity
- Unknown
- Linked source
- emerj.com
No explicit deployment-stage evidence found.
Primary read
Use case focus
Showing 2 of 2
- 1Procurement efficiency
- 2Drug production optimization
- Integrated Bizagi’s Intelligent Process Automation to automate workflows and integrate procurement data.
- Used AI-driven statistical tools like PLS regression and CART decision trees to enhance drug production.
- Leveraged Machine Learning to analyze supply chain data and predict procurement issues.
- Incorporated data from approximately 30 process parameters to improve production and yield.
- Procurement cost savings achieved within ten weeks.
- Enhanced system access for 5,000 globally distributed employees.
Architecture
Takeda utilized Bizagi’s IPA platform consisting of modular systems, integrating procurement operations post-acquisition of Shire. AI-driven statistical tools such as PLS regression and CART trees were leveraged in their Switzerland branch to optimize drug production by analyzing multiple process parameters.
Sources & evidence1
- Customer explicitly identified
- Recent evidence check available
- Last evidence check: Jul 22, 2026.
The case's original source is still reachable.
- Cited source last checked Jun 12, 2026 — ok (0/1 broken).
Measures whether this deployment's public evidence persists — not whether the system is still in production.
AI-generated summary. Verify important details with the linked sources before relying on this case.
Explore related AI use cases
Was this useful?
Community
Comments
No published comments yet.